T. Rowe Price Associates’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $227M | Buy |
3,025,251
+37,411
| +1% | +$2.95M | 0.03% | 430 |
|
|
2025
Q4 | $236M | Buy |
2,987,840
+258,155
| +9% | +$19.4M | 0.03% | 418 |
|
|
2025
Q3 | $179M | Sell |
2,729,685
-396,388
| -13% | -$19.4M | 0.02% | 489 |
|
|
2025
Q2 | $124M | Sell |
3,126,073
-138,961
| -4% | -$4.55M | 0.01% | 528 |
|
|
2025
Q1 | $98.5M | Sell |
3,265,034
-561,905
| -15% | -$18.4M | 0.01% | 554 |
|
|
2024
Q4 | $134M | Sell |
3,826,939
-383,233
| -9% | -$14.3M | 0.02% | 507 |
|
|
2024
Q3 | $169M | Buy |
4,210,172
+275,861
| +7% | +$12.8M | 0.02% | 465 |
|
|
2024
Q2 | $188M | Buy |
3,934,311
+412,108
| +12% | +$16.9M | 0.02% | 431 |
|
|
2024
Q1 | $153M | Sell |
3,522,203
-732,871
| -17% | -$34.9M | 0.02% | 470 |
|
|
2023
Q4 | $215M | Buy |
4,255,074
+497,077
| +13% | +$23.8M | 0.03% | 408 |
|
|
2023
Q3 | $170M | Sell |
3,757,997
-77,870
| -2% | -$3.21M | 0.03% | 421 |
|
|
2023
Q2 | $157M | Sell |
3,835,867
-99,084
| -3% | -$3.81M | 0.02% | 435 |
|
|
2023
Q1 | $141M | Sell |
3,934,951
-357,480
| -8% | -$13.4M | 0.02% | 453 |
|
|
2022
Q4 | $162M | Sell |
4,292,431
-504,701
| -11% | -$21.2M | 0.03% | 411 |
|
|
2022
Q3 | $212M | Sell |
4,797,132
-10,258,914
| -68% | -$432M | 0.03% | 348 |
|
|
2022
Q2 | $557M | Buy |
15,056,046
+705,586
| +5% | +$26.6M | 0.07% | 269 |
|
|
2022
Q1 | $532M | Buy |
14,350,460
+1,860,180
| +15% | +$60.9M | 0.05% | 318 |
|
|
2021
Q4 | $380M | Buy |
12,490,280
+752,959
| +6% | +$23.7M | 0.03% | 400 |
|
|
2021
Q3 | $394M | Sell |
11,737,321
-521,506
| -4% | -$19.6M | 0.04% | 389 |
|
|
2021
Q2 | $489M | Sell |
12,258,827
-321,229
| -3% | -$12.6M | 0.05% | 341 |
|
|
2021
Q1 | $566M | Sell |
12,580,056
-534,911
| -4% | -$29.8M | 0.06% | 308 |
|
|
2020
Q4 | $742M | Buy |
13,114,967
+2,382,942
| +22% | +$119M | 0.08% | 264 |
|
|
2020
Q3 | $509M | Buy |
10,732,025
+2,120,663
| +25% | +$118M | 0.06% | 300 |
|
|
2020
Q2 | $508M | Buy |
8,611,362
+4,848,917
| +129% | +$270M | 0.06% | 295 |
|
|
2020
Q1 | $178M | Buy |
3,762,445
+1,898,009
| +102% | +$106M | 0.03% | 439 |
|
|
2019
Q4 | $113M | Sell |
1,864,436
-85,428
| -4% | -$5.09M | 0.01% | 631 |
|
|
2019
Q3 | $117M | Sell |
1,949,864
-35,503
| -2% | -$2.31M | 0.02% | 584 |
|
|
2019
Q2 | $128M | Sell |
1,985,367
-482,102
| -20% | -$34.1M | 0.02% | 586 |
|
|
2019
Q1 | $200M | Buy |
2,467,469
+1,318,345
| +115% | +$85M | 0.03% | 469 |
|
|
2018
Q4 | $62.1M | Buy |
1,149,124
+54,588
| +5% | +$2.78M | 0.01% | 742 |
|
|
2018
Q3 | $56.5M | Sell |
1,094,536
-107,097
| -9% | -$5.03M | 0.01% | 872 |
|
|
2018
Q2 | $50.1M | Sell |
1,201,633
-140,299
| -10% | -$6.22M | 0.01% | 898 |
|
|
2018
Q1 | $59.2M | Sell |
1,341,932
-46,646
| -3% | -$2.37M | 0.01% | 814 |
|
|
2017
Q4 | $69.8M | Buy |
1,388,578
+264,678
| +24% | +$14.5M | 0.01% | 751 |
|
|
2017
Q3 | $57M | Sell |
1,123,900
-13,321
| -1% | -$698K | 0.01% | 800 |
|
|
2017
Q2 | $57.9M | Sell |
1,137,221
-736,738
| -39% | -$34.3M | 0.01% | 777 |
|
|
2017
Q1 | $75.3M | Sell |
1,873,959
-26,646
| -1% | -$1.2M | 0.01% | 674 |
|
|
2016
Q4 | $90.9M | Buy |
1,900,605
+867,505
| +84% | +$34.3M | 0.02% | 628 |
|
|
2016
Q3 | $37.9M | Sell |
1,033,100
-307,538
| -23% | -$9.62M | 0.01% | 905 |
|
|
2016
Q2 | $31.2M | Buy |
1,340,638
+26,410
| +2% | +$852K | 0.01% | 945 |
|
|
2016
Q1 | $53.2M | Sell |
1,314,228
-86,259
| -6% | -$3.5M | 0.01% | 750 |
|
|
2015
Q4 | $86.7M | Sell |
1,400,487
-277,056
| -17% | -$14.9M | 0.02% | 593 |
|
|
2015
Q3 | $67.8M | Buy |
1,677,543
+27,738
| +2% | +$1.44M | 0.02% | 686 |
|
|
2015
Q2 | $94.9M | Buy |
1,649,805
+160,547
| +11% | +$10.2M | 0.02% | 613 |
|
|
2015
Q1 | $94.8M | Sell |
1,489,258
-1,189,120
| -44% | -$80.7M | 0.02% | 637 |
|
|
2014
Q4 | $165M | Sell |
2,678,378
-76,372
| -3% | -$3.77M | 0.04% | 481 |
|
|
2014
Q3 | $107M | Sell |
2,754,750
-11,528
| -0.4% | -$409K | 0.02% | 592 |
|
|
2014
Q2 | $95.3M | Sell |
2,766,278
-462,979
| -14% | -$14.6M | 0.02% | 648 |
|
|
2014
Q1 | $140M | Sell |
3,229,257
-120,158
| -4% | -$5.82M | 0.03% | 528 |
|
|
2013
Q4 | $133M | Sell |
3,349,415
-63,630
| -2% | -$2.27M | 0.03% | 532 |
|
|
2013
Q3 | $128M | Sell |
3,413,045
-422,710
| -11% | -$12.6M | 0.03% | 523 |
|
|
2013
Q2 | $103M | Buy |
+3,835,755
| New | +$81.6M | 0.03% | 563 |
|
Other funds holding IONS
VPM
VCM
T. Rowe Price Associates's IONS Position: Q1 2026 in Review
T. Rowe Price Associates increased its Ionis Pharmaceuticals (IONS) stake by 1.3% in Q1 2026, buying an estimated $2.95M and bringing the position to 3,025,251 shares worth $227M. The position accounts for 0.03% of the portfolio, ranked #430.
T. Rowe Price Associates first reported a position in IONS in Q2 2013 and has held it in 52 quarters since. The position peaked at $742M in Q4 2020. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- T. Rowe Price Associates held 3,025,251 shares of Ionis Pharmaceuticals worth $227M as of Q1 2026.
- T. Rowe Price Associates bought 37,411 Ionis Pharmaceuticals shares in Q1 2026, an estimated $2.95M.
- Ionis Pharmaceuticals made up 0.03% of T. Rowe Price Associates's portfolio in Q1 2026, its #430 holding.
- T. Rowe Price Associates first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- T. Rowe Price Associates's Ionis Pharmaceuticals position peaked at $742M in Q4 2020.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.